Evidence map›Paper›PMID 42630237›Full record

ArticleFrontiers in cellular and infection microbiology2026

Essential fatty acids disrupt the mycolic acid-rich cell envelope of clinical

Ming Wei, Shiwang Xie, Peng Wang, Tianmeng Li, Jun Liu, Jingxian Yang, Xinmin Xu, Dan Luo, Li Gu, Shuai Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ming WeiDepartment of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Shiwang XieCAS Center for Excellence in Nanoscience, Beijing Key Laboratory of Micro-Nano Energy and Sensor, Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, China.
Peng WangDepartment of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Tianmeng LiDepartment of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Jun LiuDepartment of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Jingxian YangDepartment of Clinical Laboratory, Aerospace Center Hospital, Beijing, China.
Xinmin XuDepartment of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Dan LuoCAS Center for Excellence in Nanoscience, Beijing Key Laboratory of Micro-Nano Energy and Sensor, Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences, Beijing, China.
Li GuDepartment of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Shuai WangNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Conventional antibiotics against slow-growing, mycolic acid-rich Methods: Five essential fatty acids were screened against 82 clinical Results: α-Linolenic acid, γ-linolenic acid, eicosapentaenoic acid and DHA exhibited comparable activity (MIC Conclusions: These findings demonstrate that DHA displays rapid membrane-disruptive activity and can enhance amikacin activity against

Indexed as

Anti-Bacterial AgentsCell MembraneCell WallMycolic AcidsNocardiaNocardia InfectionsAmikacinGene Expression ProfilingHumansMicrobial Sensitivity TestsMicrobial ViabilityMicroscopy, Electron, ScanningTobramycinAmikacinAnti-Bacterial AgentsMycolic AcidsTobramycinamikacin combinationessential fatty acidsmembrane disruptionmycolic acidNocardia

Identifiers

PMID42630237
PMCPMC13493296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.